chapter
recogn
risk
manifest
common
opportunist
infect
renal
transplant
recipi
admit
intens
care
unit
describ
appropri
evalu
treatment
infect
renal
transplant
recipi
admit
intens
care
unit
posttranspl
mani
infect
concern
cmv
ebv
bk
viru
particular
risk
regard
acut
longterm
complic
patient
allograft
chronic
kidney
diseas
ckd
pervas
throughout
world
result
increas
need
renal
transplant
unfortun
current
donor
pool
live
cadaver
meet
increas
need
potenti
recip
given
favor
surviv
rate
patient
receiv
renal
transplant
compar
dialysi
need
expect
continu
rise
improv
surgic
techniqu
preand
posttranspl
care
evolut
immunosuppress
regimen
aid
graft
surviv
function
howev
immunosuppress
also
result
increas
risk
posttranspl
complic
particularli
infect
infect
paramount
continu
portend
signific
morbid
mortal
among
transplant
recipi
sourc
infect
among
renal
transplant
recipi
rtr
includ
reactiv
latent
infect
recipi
donorderiv
infect
de
novo
posttranspl
infect
includ
immedi
postop
nosocomi
communityacquir
infect
underli
comorbid
malnutrit
diabet
obes
cirrhosi
also
may
increas
overal
risk
infect
factor
directli
relat
transplant
includ
hospit
surgic
procedur
need
support
equip
urinari
cathet
endotrach
tube
central
line
provid
potenti
sourc
infect
postop
intens
immunosuppress
therapi
use
prevent
acut
reject
preserv
renal
graft
function
level
durat
immunosuppress
correl
increas
risk
develop
opportunist
infect
thu
despit
advanc
manag
immunosuppress
fine
balanc
exist
quantiti
immunosuppress
need
prevent
cruzi
coccidioid
spp
histoplasma
spp
west
nile
viru
pretranspl
vaccin
may
reduc
morbid
mortal
pathogen
often
includ
pneumococc
season
influenza
combin
tetanu
diphtheria
pertussi
varicella
zoster
virus
measl
mump
rubella
human
papillomaviru
age
depend
hepat
b
infecti
complic
posttransplant
typic
categor
base
tempor
relat
transplant
fig
risk
acut
cellular
reject
highest
first
sever
month
transplant
patient
given
induct
immunosuppress
periop
subsequ
place
longterm
mainten
immunosuppress
effect
induct
immunosuppress
often
last
month
depend
graft
function
occurr
reject
reject
superimpos
risk
infect
infect
immunocompromis
host
carri
broad
spectrum
potenti
pathogen
atyp
present
infect
compar
gener
popul
infecti
risk
transplant
result
immunosuppress
pretranspl
evalu
donor
recipi
complet
minim
risk
pretranspl
evalu
manag
may
vari
across
transplant
center
thorough
medic
histori
includ
travel
prior
infect
environment
exposur
immun
histori
obtain
common
bacteri
urinari
pathogen
rtr
includ
enterobacteriacea
flora
recipi
escherichia
coli
proteu
spp
klebsiella
spp
pseudomona
aeruginosa
nosocomi
pathogen
enterococcu
speci
also
common
controversi
remain
literatur
regard
whether
uti
result
increas
risk
allograft
dysfunct
reject
asymptomat
bacteruria
common
persist
bacteruria
associ
allograft
infect
acut
reject
studi
howev
demonstr
reduct
symptomat
uti
via
treatment
asymptomat
bacteruria
lack
literatur
controversi
remain
literatur
consensu
treatment
asymptomat
bacteruria
reach
transplant
program
use
practic
patient
receiv
tmpsmz
pneumocyst
jiroveci
prophylaxi
may
lower
risk
asymptomat
bacteruria
uti
mainten
immunosuppress
wean
time
howev
rare
stop
unless
allograft
fail
remov
cours
complic
reject
patient
often
requir
augment
immunosuppress
prolong
intens
immunosuppress
increas
risk
opportunist
infect
effort
reduc
risk
common
infect
antimicrobi
prophylaxi
often
use
infect
occur
first
month
transplant
usual
relat
transplant
complic
result
surgeri
includ
prolong
ischem
time
leakag
strictur
urinari
vascular
anastomos
increas
risk
superfici
deep
surgic
site
infect
nosocomi
pathogen
common
infect
kidney
transplant
urinari
tract
infect
occur
shortli
procedur
urin
cultur
donor
recipi
obtain
immedi
transplant
typic
recipi
receiv
cours
antibiot
direct
pathogen
guid
suscept
test
nosocomi
infect
includ
pneumonia
central
venou
catheterrel
infect
clostridium
difficil
infect
seen
time
reactiv
herp
simplex
varicella
zoster
virus
hsv
vzv
also
may
manifest
earli
period
absenc
antivir
prophylaxi
effect
stress
transplant
immunosuppress
unusu
donorderiv
infect
includ
freeliv
amoeba
lymphocyt
choriomening
viru
lcmv
rabi
viru
west
nile
viru
report
period
shortli
thereaft
consid
patient
develop
unexplain
sign
symptom
laboratori
find
concern
process
opportunist
infect
occur
commonli
month
transplant
often
caus
reactiv
latent
infect
center
use
trimethoprimsulfamethoxazol
prophylaxi
pneumocysti
jiroveci
also
offer
protect
infect
result
listeria
spp
nocardia
spp
toxoplasma
spp
urinari
gastrointestin
pathogen
howev
prescrib
taken
aforement
infect
seen
viral
infect
also
common
patient
receiv
antivir
prophylaxi
prevent
reactiv
hsv
vzv
cytomegaloviru
cmv
infect
problemat
atrisk
patient
viral
infect
includ
bk
viru
adenoviru
ebv
also
occur
time
reactiv
tuberculosi
endemicdimorph
fungi
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
also
consid
patient
appropri
clinic
scenario
exposur
patient
requir
treatment
reject
continu
risk
opportunist
infect
requir
intens
immunosuppress
absenc
reject
infect
occur
month
posttransplant
part
similar
seen
gener
correl
home
countri
activ
infect
tuberculosi
portend
increas
morbid
mortal
transplant
patient
pretranspl
screen
may
fals
neg
anerg
respons
set
endstag
renal
diseas
esrd
recipi
diagnos
suspect
latent
tb
treatment
isoniazid
typic
would
initi
transplant
patient
may
undergo
renal
transplant
receiv
isoniazid
latent
tuberculosi
classic
present
activ
tb
includ
cough
fever
malais
night
sweat
weight
loss
howev
set
immunosuppress
patient
may
extrapulmonari
symptomssit
infect
divers
spectrum
clinic
radiolog
find
includ
cavitari
noncavitari
lesion
seen
consider
activ
infect
prompt
respiratori
isol
neg
pressur
extern
vent
singl
room
avoid
patienttopati
spread
tuberculin
skin
test
interferon
gamma
releas
assay
intend
assess
latent
tuberculosi
activ
infect
therefor
cultur
nucleic
acid
test
tissu
specimen
stain
acidfast
bacilli
obtain
confirm
diagnosi
drug
suscept
test
combin
treatment
initi
assist
infecti
diseas
transplant
team
regimen
adjust
requir
base
drugdrug
interact
side
effect
profil
nontubercul
mycobacteri
infect
possibl
may
occur
atyp
includ
dissemin
among
transplant
recipi
specif
test
includ
acidfast
stain
mycobacteri
cultur
media
request
organ
consid
differenti
diagnosi
nocardiosi
rel
rare
opportunist
infect
among
rtr
may
occur
local
infect
system
diseas
includ
multipl
cavitari
masslik
pulmonari
lesion
without
associ
hematogen
spread
skin
central
nervou
system
viscera
clinic
manifest
organ
involv
may
subtl
absent
nocardiosi
diagnos
brain
imag
perform
evalu
central
nervou
system
involv
infect
predilect
spread
brain
may
present
minim
symptom
therapi
may
includ
decreas
immunosuppress
surgeri
antimicrobi
empir
treatment
includ
least
two
three
agent
potenti
efficaci
nocardia
strain
take
account
site
infect
cn
penetr
may
necessari
antimicrobi
therapi
usual
prolong
cours
month
base
antimicrobi
suscept
incid
nocardiasi
fallen
possibl
secondari
improv
immunosuppress
practic
andor
standard
use
tmpsmx
prophylaxi
pneumocysti
jiroveci
viral
infect
renal
transplant
patient
wide
rang
present
potenti
shortterm
longterm
sequela
suscept
infect
allograft
dysfunct
reject
malign
exposur
virus
may
constitut
primari
infect
recipi
prior
viralspecif
immun
may
repres
secondari
infect
wherebi
dormant
strain
bacteri
pneumonia
may
aris
divers
spectrum
pathogen
commun
nosocomi
exposur
clinic
manifest
pneumonia
may
subtler
initi
requir
clinician
maintain
high
level
suspicion
diagnost
workup
consist
respiratori
sampl
sputum
nasal
swab
viral
pathogen
tracheal
secret
andor
bronchoalveolar
lavag
bal
urin
streptococc
legionella
antigen
also
appropri
blood
cultur
drawn
set
sepsi
ascertain
concomit
bloodstream
infect
possibl
metastat
site
infect
may
alter
antimicrobi
choic
durat
therapi
aureu
pseudomona
enter
gramneg
bacilli
account
major
case
nosocomi
set
organ
cover
empir
patient
pneumonia
cultur
data
avail
pneumonia
common
communityacquir
bacteri
respiratori
pathogen
patient
greater
month
transplant
augment
immunosuppress
reject
legionella
remain
potenti
sporad
epidem
pathogen
clinician
must
recogn
need
atyp
coverag
macrolid
quinolon
empir
antimicrobi
therapi
base
exposur
risk
antibiogram
individu
patient
issu
allergi
drug
interact
comorbid
tailor
appropri
suscept
pleas
refer
publish
guidelin
detail
unit
state
approxim
patient
undergo
renal
transplant
develop
surgic
site
infect
ssi
ssi
among
earli
potenti
infecti
sourc
ssi
categor
depth
infect
superficialincision
deepincision
organ
space
depend
depth
ssi
may
requir
aggress
manag
debrid
infect
tissu
antimicrobi
therapi
assess
sourc
control
imag
rule
abscess
superfici
infect
may
valu
also
set
previous
mention
infect
pathogen
includ
nosocomi
exposur
mrsa
vre
pseudomona
skin
flora
enterobacteriacea
among
common
pathogen
ssi
thu
empir
coverag
reflect
clostridium
difficil
infect
cdi
remain
common
caus
nosocomi
infecti
diarrhea
transplant
patient
mani
risk
factor
acquisit
increas
sever
cdi
antimicrobi
use
common
given
risk
posttranspl
infect
primari
modifi
risk
factor
recent
surgic
procedur
immunosuppress
also
increas
overal
risk
although
diarrhea
may
common
popul
clinician
low
threshold
test
cdi
initi
empir
therapi
await
result
given
increas
risk
sever
diseas
test
cdi
neg
evalu
infect
result
bacteria
virus
parasit
consid
mycobacterium
tuberculosi
tb
endem
mani
area
world
preval
among
transplant
recipi
found
threshold
load
viral
dna
rise
level
serial
test
treatment
initi
prevent
progress
cmv
syndrom
tissueinvas
diseas
firstlin
treatment
cmv
infect
typic
includ
reduc
immunosuppress
possibl
antivir
therapi
intraven
ganciclovir
oral
valganciclovir
depend
sever
ill
cmv
diseas
usual
treat
initi
intraven
ganciclovir
case
may
transit
oral
valganciclovir
pend
clinic
improv
abil
absorb
oral
medic
agent
requir
dose
adjust
set
renal
dysfunct
valganciclovir
use
patient
requir
hemodialysi
agent
caus
myelosuppress
herald
leukopenia
andor
thrombocytopenia
depend
sever
case
may
necessit
use
granulocyt
colonystimul
factor
gcsf
switch
anoth
antivir
dose
never
reduc
indic
risk
resist
treatment
cmv
diseas
gener
least
week
continu
viral
load
neg
viral
load
may
continu
rise
first
day
start
antivir
treatment
occasion
viru
develop
resist
patient
rise
viral
load
despit
day
treatment
appropri
dose
ganciclovir
valganciclovir
test
antivir
resist
initi
altern
therapi
may
indic
approv
secondlin
therapi
cmv
infect
includ
foscarnet
cidofovir
agent
potenti
caus
nephrotox
well
advers
effect
like
cmv
ebv
infect
rtr
donor
deriv
reactiv
latent
infect
recipi
asymptomat
caus
mononucleosislik
ill
malais
fever
headach
sore
throat
viru
establish
latenc
b
cell
associ
posttransplant
lymphoprolif
diseas
ptld
uncheck
prolif
b
lymphocyt
potenti
malign
transform
patient
ebv
infect
develop
ptld
risk
factor
includ
high
viral
load
ebv
cmv
seromismatch
celldeplet
agent
compar
organ
type
kidney
transplant
recipi
rel
low
risk
ptld
occur
patient
ptld
may
manifest
nodal
tissu
extranod
viscera
includ
allograft
treatment
depend
patholog
diagnosi
extent
diseas
may
includ
reduct
immunosuppress
surgic
resect
antibodi
rituximab
even
cytotox
chemotherapi
use
antivir
agent
acyclovir
ganciclovir
immunoglobulin
controversi
may
consid
adjunct
therapi
treatment
ptld
requir
multidisciplinari
approach
input
specialist
transplant
nephrolog
surgeri
oncolog
infecti
diseas
herp
simplex
viru
hsv
seropreval
unit
state
adult
popul
approxim
respect
reactiv
may
occur
seroposit
immunocompet
patient
reactiv
rtr
occur
commonli
absenc
antivir
prophylaxi
seen
earli
month
prior
exposur
reactiv
result
immunosuppress
suggest
test
viral
pathogen
discuss
individu
section
herpesviru
famili
includ
herp
simplex
virus
cytomegaloviru
cmv
varicella
zoster
viru
vzv
epsteinbarr
viru
ebv
human
herpesvirus
virus
establish
latenc
initi
infect
reactiv
period
immunosuppress
import
viral
pathogen
polyoma
jcbk
virus
parvoviru
adenoviru
rotaviru
noroviru
respiratori
virus
viral
hepatitid
cmv
common
signific
viral
infect
rtr
spectrum
ill
rang
asymptomat
viremia
cmv
syndrom
tissueinvas
diseas
asymptomat
viremia
defin
viru
detect
blood
nucleic
acid
test
nat
without
associ
clinic
laboratori
manifest
depend
quantit
viral
load
time
posttransplant
patient
asymptomat
viremia
often
requir
either
antivir
therapi
close
monitor
ensur
infect
progress
diseas
cmv
syndrom
occur
patient
constitut
symptom
fever
malais
myalgia
andor
laboratori
find
leukopenia
thrombocytopenia
set
viremia
cmv
tissueinvas
diseas
character
focal
tissu
inflamm
caus
viral
invas
biopsi
demonstr
cytopath
effect
viru
intranuclear
inclus
patient
cmv
diseas
usual
also
higher
viral
load
biopsi
perform
patient
sometim
treat
empir
set
characterist
symptom
radiograph
find
cmv
viremia
common
organ
system
involv
gastrointestin
tract
pneumon
hepat
retin
nephriti
also
occur
sever
present
cmv
pneumon
patient
often
sever
ill
diagnosi
treatment
cmv
diseas
often
undertaken
input
infecti
diseas
specialist
addit
direct
effect
mention
cmv
infect
associ
numer
indirect
effect
cmv
immunomodulatori
viru
increas
suscept
variou
coinfect
cmv
infect
also
lead
acut
andor
chronic
allograft
dysfunct
associ
increas
mortal
base
upon
pretranspl
serolog
recipi
seroneg
receiv
organ
donorposit
donor
highest
risk
cmv
infect
progress
cmv
diseas
refer
cmv
mismatch
recipi
posit
antibodi
igg
cmv
transplant
cmv
dr
cmv
dr
consid
intermediaterisk
recipi
cmv
infect
case
donor
recipi
seroneg
lowest
risk
cmv
infect
import
receiv
cmvneg
leukocytedeplet
blood
product
avoid
iatrogen
transmiss
patient
high
intermedi
risk
cmv
infect
receiv
induct
therapi
treatment
acut
reject
antilymphocyt
agent
increas
risk
cmv
infect
subsequ
month
effort
reduc
cmv
infect
diseas
well
indirect
effect
sever
prevent
strategi
implement
one
option
provid
antivir
prophylaxi
intraven
ganciclovir
oral
valganciclovir
atrisk
individu
highrisk
period
anoth
option
preemptiv
monitor
entail
period
monitor
nat
patient
immunomodulatori
properti
may
marker
increas
risk
coinfect
report
infrequ
caus
graft
dysfunct
bone
marrow
suppress
enceph
pneumon
hepat
associ
kaposi
sarcoma
vascular
endotheli
tumor
caus
cutan
mucos
viscer
diseas
particularli
common
transplant
recipi
african
mediterranean
middl
eastern
origin
seropreval
unit
state
transmiss
shown
occur
via
renal
allograft
also
known
caus
primari
effus
lymphoma
pel
multicentr
castleman
diseas
lymphoprolif
process
seen
commonli
hiv
popul
serolog
studi
demonstr
adult
seroposit
bk
viru
bkv
rout
transmiss
thought
via
respiratori
gi
tract
follow
asymptomat
viremia
viru
establish
latenc
urinari
tract
asymptomat
viral
shed
normal
popul
viru
uniqu
pathogenesi
renal
transplant
hematopoiet
stem
cell
transplant
hsct
recipi
result
two
diseas
process
popul
polyomaviru
associ
nephropathi
pyvan
polyomavirusassoci
hemorrhag
cystiti
pyvhc
pyvhc
occur
much
frequent
hsct
popul
observ
rtr
well
process
herald
dysuria
hematuria
sometim
caus
urinari
obstruct
result
blood
clot
pyvan
common
diseas
present
rtr
occur
result
highlevel
viral
replic
urin
progress
viremia
diagnosi
suspect
rtr
declin
allograft
dysfunct
patient
highlevel
viruria
decoy
cell
shed
bkv
viremia
reject
also
includ
differenti
requir
differ
manag
renal
biopsi
usual
undertaken
differenti
two
stage
sever
diagnosi
pyvan
confirm
reduct
immunosuppress
first
import
intervent
use
immunoglobulin
antivir
agent
controversi
definit
data
provid
benefit
associ
toxic
previous
studi
antivir
agent
includ
cidofovir
leflunomid
fluoroquinolon
adenovirus
classifi
seven
subgroup
g
encompass
viral
serotyp
serotyp
capabl
establish
latent
infect
reactiv
transmit
via
allograft
viru
transmit
varieti
mode
includ
via
aerosol
bodili
fluid
caus
symptomat
diseas
immunocompet
immunocompromis
much
higher
likelihood
caus
dissemin
diseas
immunocompromis
adenoviru
caus
wide
varieti
ill
includ
upper
lower
respiratori
tract
infect
conjunct
enter
hepat
adenoviru
anoth
caus
hemorrhag
cystiti
allograft
dysfunct
similar
present
bkv
also
associ
reject
risk
factor
includ
younger
age
given
lower
likelihood
immun
treatment
lymphocytedeplet
agent
posttransplant
present
may
rang
mucocutan
lesion
oropharynx
genit
region
dissemin
throughout
multipl
organ
system
hepat
pneumon
esophag
cn
diagnosi
mucocutan
hsv
infect
clinic
direct
observ
characterist
lesion
unroof
vesicular
lesion
swab
confirmatori
test
either
polymeras
chain
reaction
pcr
direct
fluoresc
antibodi
dfa
may
help
diagnosi
treatment
hsv
kerat
retin
requir
referr
ophthalmologist
dissemin
organ
diseas
dna
detect
pcr
affect
fluid
tissu
often
prefer
diagnost
test
obtain
cell
tissu
cytoor
histopatholog
intranuclear
inclus
stain
hsv
antigen
help
confirm
diagnosi
alway
feasibl
treatment
mucocutan
hsv
infect
typic
oral
acyclovir
famciclovir
valacyclovir
cours
dissemin
hsv
hepat
meningoenceph
immunosuppress
ideal
reduc
intraven
acyclovir
mgkg
mg
kg
cn
dose
sever
viscer
diseas
everi
hour
administ
dose
adjust
base
renal
function
prophylaxi
hsv
vzv
discuss
later
oral
acyclovir
famciclovir
valacyclovir
often
given
posttranspl
period
augment
immunosuppress
ganciclovir
valganciclovir
treatment
prevent
cmv
also
activ
hsv
vzv
although
antivir
resist
less
common
hsv
cmv
occur
consid
patient
fail
respond
treatment
genotyp
test
resist
altern
therapi
avail
varicellazost
viru
vzv
respons
chickenpox
spread
via
direct
contact
droplet
inhal
primari
infect
hsv
viru
also
establish
latenc
nerv
root
reactiv
immunocompet
immunocompromis
individu
us
adult
viru
childhood
varicella
vaccin
introduc
use
unit
state
young
adult
seroposit
result
vaccin
vzv
igg
test
perform
part
transplant
workup
vaccin
nonimmun
gener
recommend
contraind
least
week
transplant
reactiv
vzv
rtr
occur
singl
multipl
dermatom
skin
erupt
dissemin
infect
viscer
cn
involv
diagnosi
usual
clinic
often
confirm
use
vzv
pcr
dfa
dissemin
cn
viscer
diseas
dna
detect
pcr
affect
fluid
tissu
prefer
diagnost
test
obtain
cell
tissu
cytoor
histopatholog
intranuclear
inclus
immunochemistri
help
confirm
diagnosi
alway
feasibl
absenc
dissemin
diseas
oral
antivir
treatment
acyclovir
valacyclovir
famciclovir
like
adequ
concern
dissemin
infect
cn
organ
involv
dissemin
infect
vzv
requir
intraven
acyclovir
day
also
establish
latenc
initi
infect
reactiv
may
approxim
infect
popul
result
prophylaxi
fungal
pathogen
recommend
routin
rtr
howev
casefat
rate
highest
fungal
infect
compar
pathogen
categori
therefor
infect
occur
prompt
recognit
treatment
import
fungal
infect
occur
within
first
month
transplant
although
longer
period
risk
may
occur
heavili
immunosuppress
recipi
infect
result
candida
speci
repres
common
fungal
infect
rtr
older
age
central
venou
cathet
surgic
drain
urinari
cathet
diabet
mellitu
use
corticosteroid
broadspectrum
antibiot
length
hospit
intens
care
unit
stay
import
risk
factor
develop
candida
infect
transplant
recipi
candidiasi
categor
either
superfici
deep
commonli
involv
superfici
site
oral
caviti
esophagu
bladder
oral
candidiasi
manifest
singl
multipl
white
rais
plaquelik
lesion
palat
oropharyng
mucou
membran
often
treat
topic
agent
oral
candidiasi
progress
distal
lead
esophag
involv
symptom
rang
asymptomat
odynophagiadysphagia
esophag
candidiasi
untreat
lead
esophag
bleed
perfor
dissemin
candidiasi
case
candida
spp
isol
sputum
bal
cultur
thought
colon
contamin
usual
requir
treatment
candiduria
may
repres
asymptomat
colon
renal
recipi
indwel
bladder
cathet
versu
lower
upper
tract
infect
candiduria
rtr
theoret
lead
ascend
infect
involv
ureter
anastomosi
allograft
clinic
bia
treat
even
asymptomat
candiduria
recent
renal
recipi
ration
therapeut
option
includ
azol
amphotericin
b
bladder
irrig
echinocandin
poor
urinari
penetr
therefor
recommend
treat
uti
deepseat
candidiasi
manifest
persist
fever
sepsi
patient
receiv
antibacteri
therapi
risk
factor
candidiasi
definit
diagnosi
invas
candidiasi
base
isol
organ
steril
sourc
eg
blood
ascit
sensit
blood
cultur
candidemia
therefor
isol
candida
one
blood
cultur
alway
consid
repres
true
pathogen
candidemia
may
result
deep
tissueinvas
candidiasi
catheterrel
infect
case
line
remov
recommend
strongli
rtr
candidemia
lead
metastat
infect
renal
vascular
anastomosi
renal
parenchyma
sign
dissemin
includ
skin
lesion
new
ocular
symptom
includ
eye
pain
photophobia
visual
loss
may
signifi
candida
endophthalm
prompt
ophthalmolog
evalu
dilat
eye
exam
treatment
deepseat
candida
infect
candidemia
requir
system
antifung
agent
option
includ
azol
echinocandin
liposom
amphotericin
b
patient
sever
infect
risk
resist
candida
spp
firstlin
treatment
usual
echinocandin
patient
stabl
signific
exposur
azol
fluconazol
reason
option
speci
identifi
treatment
guid
like
suscept
prolif
cryptococcu
neoforman
ubiquit
encapsul
yeast
variabl
present
diagnosi
may
challeng
usual
base
molecular
detect
pcr
histopatholog
manag
infect
usual
includ
reduct
immunosuppress
antivir
agent
specif
cidofovir
lipid
conjug
brincidofovir
use
treatment
signific
infect
current
approv
drug
indic
brincidofovir
commerci
avail
time
write
import
communityacquir
respiratori
viru
infect
immunocompromis
host
includ
influenza
viru
type
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
coronaviru
rhinoviru
human
metapneumoviru
hmpv
virus
transmit
direct
contact
respiratori
droplet
infect
individu
typic
follow
season
pattern
clinic
present
made
includ
upper
respiratori
tract
infect
tracheobronch
influenzalik
ill
bronchiol
pneumonia
immunocompromis
host
viral
shed
may
persist
month
difficult
distinguish
infect
base
clinic
present
therefor
make
definit
diagnosi
multiplex
pcr
assay
respiratori
specimen
use
viral
antigen
test
influenza
rsv
also
perform
sensit
lower
influenza
typic
sever
aforement
viral
infect
treatment
neuraminidas
inhibitor
oseltamivir
zanamivir
usual
indic
may
shorten
durat
symptom
prevent
progress
sever
ill
newer
agent
intraven
peramivir
use
routin
critic
ill
immunocompromis
patient
treatment
recommend
review
yearli
updat
recommend
manag
season
influenza
vaccin
recommend
treatment
rest
aforement
viral
infect
usual
support
renal
transplant
popul
antivir
therapi
ribavirin
use
treat
rsv
hmpv
piv
lung
transplant
hsct
popul
reserv
sever
infect
administ
direct
infecti
diseas
specialist
pretranspl
manag
viral
hepat
imper
infect
affect
morbid
mortal
transplant
set
hepat
c
particular
concern
blunt
immun
system
treat
transplant
hcv
infect
secondari
cryoglobulinemia
may
affect
neg
graft
function
posttranspl
hbv
hcv
reactiv
immunosuppress
receiv
infect
donor
organ
develop
activ
infect
variabl
present
rapid
clinic
progress
set
immunosuppress
antibodi
may
form
seroconvers
thu
nucleic
acid
test
use
assess
infect
fungal
infect
among
solid
organ
transplant
recipi
rtr
lowest
rate
invas
fungal
infect
ifi
account
transplant
carri
approxim
mortal
rate
rtr
infect
pathogen
decreas
among
popul
univers
use
chemoprophylaxi
among
transplant
center
first
sever
month
posttranspl
tmpsmx
prefer
agent
altern
option
includ
atovaquon
dapson
inhal
pentamidin
agent
less
effect
breakthrough
infect
occur
symptom
pjp
includ
fever
dyspnea
nonproduct
cough
hypoxia
sever
expect
imag
radiograph
comput
tomographi
ct
scan
often
reveal
presenc
interstiti
infiltr
often
character
ground
glass
appear
diagnosi
depend
identifi
organ
via
respiratori
secret
sputum
bal
tissu
specimen
usual
made
via
appropri
stain
silver
giemsa
molecular
techniqu
pcr
therapi
consist
day
highdos
intraven
tmpsmx
dosag
adjust
accord
kidney
function
case
sulfa
hypersensit
intraven
pentamidin
atovaquon
clindamycin
pyrimethamin
tmp
plu
dapson
defici
must
test
administr
medic
addit
corticosteroid
consid
signific
hypoxia
partial
pressur
oxygen
alveoli
mm
hg
room
air
p
jiroveci
pneumonia
like
sever
infect
requir
reduct
immunosuppress
central
nervou
system
cn
infect
common
gener
popul
fatal
clinician
must
maintain
high
level
suspicion
cn
infect
transplant
recipi
immunosuppress
therapi
may
result
subtl
present
typic
infect
opportunist
pathogen
also
may
result
vari
clinic
present
fever
headach
remain
among
reliabl
present
symptom
exampl
potenti
infect
includ
communityacquir
mening
mass
lesion
bacteri
brain
abscess
invas
aspergillosi
nocardiosi
toxoplasmosi
cryptococcu
viral
infect
may
result
syndrom
mening
meningoenceph
includ
mani
herpesvirus
eg
hsv
vzv
jc
viru
rare
result
progress
multifoc
leuko
encephalopathi
pml
transplant
patient
may
experi
headach
fever
nuchal
rigid
impair
conscious
chang
cognit
function
final
noninfecti
caus
cn
syndrom
also
must
consid
includ
drug
toxic
posterior
revers
encephalopathi
syndrom
pre
low
threshold
lumbar
punctur
spinal
fluid
analysi
fever
neurolog
symptom
focal
neurolog
symptom
requir
imag
magnet
reson
imag
mri
particularli
may
provid
import
diagnost
clue
empir
manag
presum
meningitisenceph
often
includ
vancomycin
thirdor
fourthgener
cephalosporin
carbapenem
ampicillin
possibl
listeria
infect
intraven
highdos
acyclovir
await
csf
analysi
renal
transplant
perform
patient
hiv
less
commonli
may
acquir
posttranspl
patient
found
soil
pigeon
fece
although
main
portal
entri
respiratori
tract
cryptococcu
pneumonia
seen
rel
infrequ
concern
infect
dissemin
hematogen
spread
central
nervou
system
lead
subacut
mening
diagnosi
requir
detect
cryptococcu
cerebrospin
fluid
india
ink
stain
identif
cryptococc
antigen
cultur
treatment
requir
combin
therapi
amphotericin
b
lipid
formul
amphotericin
b
sever
week
follow
fluconazol
cerebrospin
fluid
csf
cultur
neg
endem
mycos
histoplasmosi
coccidiomycosi
blastomycosi
consid
enigmat
pulmonari
cutan
complex
dissemin
present
patient
nativ
travel
one
classic
geograph
area
preval
fungi
common
term
dimorph
grow
yeast
warmer
temperatur
bodi
myceli
form
cooler
temperatur
lab
therefor
appear
yeast
histopatholog
grow
mold
cultur
serolog
fungal
antigen
eg
urin
serum
bal
fluid
stain
cultur
nucleic
acid
test
possibl
method
achiev
diagnosi
sever
diseas
liposom
amphotericin
prefer
initi
drug
eventu
transit
azol
pend
organ
involv
clinic
cours
infect
reactiv
latent
infect
donor
deriv
occur
de
novo
posttransplant
infect
result
filament
fungi
also
known
mold
least
common
ifi
rtr
aspergillu
infect
acquir
airborn
transmiss
spore
sinus
respiratori
tract
outbreak
report
among
patient
proxim
hospit
construct
site
recent
public
case
identifi
year
institut
risk
factor
includ
chronic
obstruct
pulmonari
diseas
copd
graft
dysfunct
reject
occurr
infect
common
speci
aspergillu
fumigatu
aspergillu
flavu
aspergillu
terreu
lung
common
initi
site
infect
may
manifest
solitari
multipl
nodul
cavitari
lesion
may
invad
pulmonari
vasculatur
hematogen
dissemin
organ
includ
brain
infrequ
occur
high
mortal
rate
voriconazol
without
second
activ
agent
echinocandin
lipid
amphotericin
b
emerg
firstlin
treatment
aspergillosi
coupl
reduct
immunosuppress
occasion
surgic
resect
isol
lung
brain
lesion
treatment
durat
depend
clinic
radiograph
improv
well
abil
reduc
immunosuppress
surgic
resect
less
common
myceli
fungi
clinic
import
includ
caus
zygomycosi
mucor
rhizomucor
pseudallescheria
boydii
dematiac
pigment
mold
fusarium
other
pneumocyst
jiroveci
pjp
formerli
call
pneumocysti
carinii
pcp
caus
sever
pneumonia
